Breaking News

Asymchem Completes HPAPI Facility Inspection

By the US FDA at their Tianjin1 site, a dedicated HPAPI development and manufacturing facility

Asymchem has announced that its Tianjin1 site, a dedicated High Potency Active Pharmaceutical Ingredients (HPAPI) development and manufacturing facility, successfully completed a U.S. Food and Drug Administration general GMP reinspection conducted between January 14-18, 2019. No Form 483 was issued. Previous USFDA inspections of Tianjin1 took place in 2014, also with no 483. Asymchem Laboratories (Tianjin) Co., Ltd., otherwise known as Tianjin1, produces Dexmedetomidine HCl, for which Asymche...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters